By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Islet Sciences 

641 Lexington Avenue, 6th Floor

New York  New York  10022  U.S.A.
Phone: 646-863-6341 Fax: n/a



Company News
Islet Sciences COO To Present At Metabolic Leaders Forum 3/24/2015 10:16:24 AM
Islet Sciences. COO To Present At EASL: Remogliflozin Etabonate As Novel Treatment For Non-Alcoholic Steatohepatitis (NASH) 3/9/2015 8:15:10 AM
Islet Sciences Confirms Issuance Of U.S. Patent For Using SGLT2 Inhibitors To Treat NASH/NAFLD 3/5/2015 7:32:23 AM
Islet Sciences Enters Into Exclusive License Agreement For Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate 3/3/2015 7:47:03 AM
Islet Sciences Engages Investment Bank As Financial Advisor 2/9/2015 7:17:48 AM
Islet Sciences And BHV Announce Publication Of Two Phase 2b Clinical Studies Of Remogliflozin Etabonate For Treating Type 2 Diabetes 10/23/2014 10:39:35 AM
Islet Sciences Announces Exclusive Licensing Agreement Between BHV Pharma, Inc. And Libbs Farmaceutica To Develop And Commercialize SGLT2 Inhibitor Remogliflozin Etabonate 10/6/2014 7:34:51 AM
Islet Sciences, BHV Pharma, Inc. Merges; Combined Company To Be Named Avogenx 10/1/2014 6:39:15 AM
Islet Sciences Receives Notice Of Allowance For U.S. Patent Covering Novel IL-12 Inhibitors 8/6/2014 9:28:30 AM
Islet Sciences Announces Peer-Reviewed Publication Of Study Validating Novel Diabetes Diagnostic 7/16/2014 6:51:17 AM